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Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic 
liver disease: a cautionary note on a promising technique 
 
To the Editor: 
 
We have read the article by Pavlides et al.[1] with great interest.  The potential of quantitative MR 
methods to predict clinical outcomes in patients with chronic liver disease is an important area of 
research and T1 mapping is undoubtedly a promising technique[2, 3].  The findings of Pavlides et al 
are therefore of potential importance. 
 We are however concerned that the study sample size and event rate are too small to draw 
definitive conclusions and so must be more cautious before we can assume clinical utility of T1 
mapping for prognostication.  Using a single-slice multimethod MR protocol (T1 mapping ‘corrected’ 
with T2* mapping data and MR spectroscopy), the authors monitored outcomes in just over 100 
patients on average 27 months following an initial MRI scan.  Their survival analysis is however 
based on adverse events in just 10 subjects (a number that reduces to 6 once patients with index 
decompensation at the initial MRI study are excluded).  Comparatively, this sample size and event 
rate are much lower than comparable outcome studies for competitive biomarkers (e.g. FibroScan: 
n=2052, 87 adverse events[4]; enhanced liver fibrosis test: n=457, 61 adverse events[5]). 
 The authors propose a so-called ‘Liver Inflammation Fibrosis’ (LIF) score (a metric based on 
“corrected” T1 (cT1) which is unreferenced) and report a negative predictive value of 100% for 
adverse events using a cut-off of <2 (confidence interval 94-100%).  However the positive predictive 
value for adverse events using this LIF score cut off is just 18% (confidence interval 9-30%). Thus only 
1 out of 5 patients with an LIF>2 are likely to experience an adverse event.  We agree that a LIF score 
<2 may be useful as a screening tool to identify those less likely to experience future complications, 
but as a tool to predict adverse clinical outcomes the data presented suggests LIF is actually 
relatively weak.  Indeed, using the study data, the positive predictive value of an Ishak score of 5-6 is 
slightly better, but even then just 29% (9 events in 31 patients). This, taken together with the 
existing literature, highlights the intrinsic limitations of fibrosis scores in predicting clinical outcomes.  
There is for example, a significant representation of steatohepatitis in the 10 patients with liver 
events, for whom non-invasive scores such as the CLIF-C AD score have good predictive utility 
(AUROC>0.75)[6].  Comparisons with more established surrogate endpoints for disease progression 
such as hepatic venous pressure gradient would also offer more robust LIF score validation[7]. 
 The survival analysis, whilst interesting, is also unfortunately compromised by the small 
sample size.  Given the small number of adverse events (n=10), application of a Bonferroni 
correction to multiple post-hoc inter-group comparisons would likely render most of the ‘strong 
tends towards significance’ for survival according to LIF groups as definitively non-significant. 
 T1 mapping is a well-established technique, and multiple methods have been described in 
the literature, including the widely used shortened modified look-locker inversion recovery 
(ShMOLLI) technique[8].  cT1 was applied in 54% of the patient cohort (presumably the remaining 
46% underwent uncorrected T1 mapping, although this is not clearly stated).  The authors speculate 
that ‘the enhanced ability of [their] technique to differentiate between histological stages may be 
due to the particular…T1 mapping technique we apply’ (referring to the use of cT1).  In fact, this 
conclusion could only be reached by comparing clinical outcome data using both cT1 and ShMOLLI 
methods. 
The authors also state that cT1 correct standard T1 measurements by ‘removing the 
confounding effect of liver iron’.  However, whether physically the correction employed here is 
capable of fully correcting for the presence of additional iron, especially when only a single slice is 
considered, should be examined more closely.  In fact, omitting liver iron correction actually 
improved the LIF hazard ratio (using the Cox regression model) for predicting adverse events.  It is 
therefore unclear whether correction for liver iron is beneficial or otherwise, and again this needs 
formal investigation.  Low grade siderosis can occur in chronic liver disease (in the absence of an iron 
  
deposition disorder) and the effect of this on hepatic parenchymal T1 remains to our knowledge 
little explored.  Data demonstrating the value of cT1 over other T1 mapping techniques in patients 
with non-iron deposition disorder chronic liver disease would be welcome in this regard. 
Parenchymal T1 measurements reflect the complex underlying tissue composition and are 
thus influenced by many factors beyond extracellular water and iron, for example fat[9] and 
proteinaceous components (including extracellular matrix). We need more studies that 
comprehensively explore the quantitative relationship between liver tissue composition and T1 
signal, before it can be concluded that cT1 measurements are a pure ‘estimate of extracellular 
water’. 
Finally, in the discussion, the authors rightly acknowledge the study is ‘a small proof of 
principle study’, but this perhaps should have been made clearer by the journal in the title and 
abstract. We agree with the authors that hepatic T1 mapping is definitely a promising approach for 
the quantification of liver pathology and that with high quality, well-powered supporting data could 
yield an important biomarker for all aetiologies of patients with chronic liver disease.  Indeed 
multiparametric MRI as a whole, inclusive of other techniques that assess perfusion, biomechanical 
properties and whole liver (rather than voxel-based) fat quantification has transformative potential 
in liver diagnostics[10]. 
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